amphotec- Amphotericin B injection, lipid complex Stati Uniti - inglese - NLM (National Library of Medicine)

amphotec- amphotericin b injection, lipid complex

intermune, inc. - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe) - injection, lipid complex - 50 mg in 10 ml - amphotec is indicated for the treatment of invasive aspergillosis in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin b deoxycholate in effective doses, and in patients with invasive aspergillosis where prior amphotericin b deoxycholate therapy has failed. amphotec should not be administered to patients who have documented hypersensitivity to any of its components, unless, in the opinion of the physician, the advantages of using amphotec outweigh the risks of hypersensitivity.

AMBISOME amphotericin B (amphotericin) B 50mg powder for injection Australia - inglese - Department of Health (Therapeutic Goods Administration)

ambisome amphotericin b (amphotericin) b 50mg powder for injection

gilead sciences pty ltd - amphotericin b, quantity: 50 mg - injection, powder for - excipient ingredients: hydrogenated soy phosphatidylcholine; sucrose; dl-alpha-tocopherol; distearoylphosphatidylglycerol; sodium succinate; cholesterol - indications: ambisome is indicated for: prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see clinical trials). ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum. indicated as at 8 september 2003 :ambisome is indicated for: prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see clinical trials). ambisome is indicated for empirical treatment of presumed fungal infections in febrile neutropaenic patients whose fever has failed to respond to broad spectrum antibiotic treatment. ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum.

DBL™ Cytarabine Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

dbl™ cytarabine

pfizer new zealand limited - cytarabine 100 mg/ml;   - solution for injection - 100 mg/ml - active: cytarabine 100 mg/ml   excipient: hydrochloric acid sodium hydroxide water for injection - cytarabine may be used alone or in combination with other chemotherapeutic agents. it is indicated for induction of remission of leukaemia, particularly for acute myeloid leukaemia, in adults and children. cytarabine has been used for remission induction in acute lymphocytic leukaemia, chronic myeloid leukaemia and erythroleukaemia; and in the treatment and maintenance therapy of meningeal leukaemia and other meningeal neoplasms.

AMBISOME FOR INJECTION 50 mgvial Singapore - inglese - HSA (Health Sciences Authority)

ambisome for injection 50 mgvial

gilead sciences singapore pte. ltd. - amphotericin b - injection, powder, for solution - 50 mg/vial - amphotericin b 50 mg/vial

VALGANCICLOVIR ACCORD Irlanda - inglese - HPRA (Health Products Regulatory Authority)

valganciclovir accord

accord healthcare limited - valganciclovir hydrochloride - film coated tablet - 450 milligram - valganciclovir

AMBISOME- amphotericin b injection, powder, lyophilized, for solution Stati Uniti - inglese - NLM (National Library of Medicine)

ambisome- amphotericin b injection, powder, lyophilized, for solution

astellas pharma us, inc. - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe) - amphotericin b 50 mg in 12.5 ml - amb isome is indicated for the following: see dosage and administration for recommended doses by indication. amb isome is contraindicated in those patients who have demonstrated or have a known hypersensitivity to amphotericin b deoxycholate or any other constituents of the product unless, in the opinion of the treating physician, the benefit of therapy outweighs the risk.

Valganciclovir Accord Tablet, film coated 450mg Malta - inglese - Medicines Authority

valganciclovir accord tablet, film coated 450mg

accord healthcare limited - valaciclovir hydrochloride - film-coated tablet - valaciclovir hydrochloride 450 mg - antivirals for systemic use